We now propose that symptomatic and genetically diagnosed individuals with ALSP and potentially other forms of AD‐like neuropathology will respond to CSF‐1R and BBB stabilising approaches to therapy as opposed to CSF‐1R inhibition‐based strategies as currently proposed. This evidence concerns the gene CSF1R and Alzheimer disease.